Crude and adjusted ORs and 95% CIs for early death from any cause
| Factor | Number of cases | Early deaths, number (%) | OR (95% CI) | |
| Unadjusted | Adjusted* | |||
| Age at diagnosis (years) | ||||
| <50 | 3800 | 88 (2.3) | 1.00 (–) | 1.00 (–) |
| 50–59 | 3739 | 91 (2.4) | 1.05 (0.78 to 1.42) | 1.41 (1.03 to 1.93) |
| 60–69 | 3042 | 148 (4.9) | 2.16 (1.65 to 2.82) | 2.61 (1.94 to 3.50) |
| 70–79 | 2643 | 270 (10.2) | 4.80 (3.75 to 6.14) | 4.62 (3.45 to 6.18) |
| ≥80 | 1813 | 383 (21.1) | 11.30 (8.89 to 14.36) | 8.05 (5.96 to 10.88) |
| Ethnicity | ||||
| Non-white | 2058 | 75 (3.6) | 1.00 (–) | 1.00 (–) |
| White | 9098 | 488 (5.4) | 1.50 (1.17 to 1.92) | 1.25 (0.96 to 1.63) |
| Not known | 3881 | 417 (10.7) | 3.18 (2.47 to 4.09) | 2.24 1.70 to 2.94) |
| Distant metastases at diagnosis | ||||
| No | 8289 | 312 (3.8) | 1.00 (–) | 1.00 (–) |
| Yes | 427 | 156 (36.5) | 14.72 (11.73 to 18.47) | 8.41 (6.49 to 10.89) |
| Not known | 6321 | 512 (8.1) | 2.25 (1.95 to 2.60) | 1.35 (1.13 to 1.60) |
| Tumour size (mm) | ||||
| <10 | 1232 | 12 (1.0) | 1.00 (–) | – |
| 10–19 | 4089 | 73 (1.8) | 1.85 (1.00 to 3.41) | – |
| 20–39 | 3186 | 83 (2.6) | 2.72 (1.48 to 5.00) | – |
| 40–49 | 2039 | 86 (4.2) | 4.48 (2.44 to 8.22) | – |
| ≥50 | 898 | 99 (11.0) | 12.60 (6.87 to 23.08) | – |
| Not known | 3593 | 627 (17.4) | 21.49 12.09 to 38.20) | – |
| Node status | ||||
| Negative | 5587 | 95 (1.7) | 1.00 (–) | – |
| Positive | 4380 | 167 (3.8) | 2.29 (1.78 to 2.96) | – |
| Not known | 5070 | 718 (14.2) | 9.54 (7.67 to 11.86) | – |
| Charlson Index (comorbidities) | ||||
| 0 (minor) | 6958 | 203 (2.9) | 1.00 (–) | 1.00 (–) |
| 1 (moderate) | 407 | 48 (11.8) | 4.45 (3.19 to 6.20) | 2.54 (1.77 to 3.65) |
| 2+ (severe) | 1615 | 231 (14.3) | 5.55 (4.56 to 6.76) | 3.55 (2.85 to 4.42) |
| Not known | 6057 | 498 (8.2) | 2.98 (2.52 to 3.52) | 1.10 (0.90 to 1.34) |
| Diagnosis date (in relation to Cancer Plan) | ||||
| Pre 2000 | 9681 | 624 (6.4) | 1.00 (–) | 1.00 (–) |
| 2000–2003 | 4189 | 292 (7.0) | 1.09 (0.94 to 1.26) | 0.90 (0.75 to 1.07 |
| Post 2003 | 1167 | 64 (5.5) | 0.84 (0.65 to 1.10) | 0.71 (0.52 to 0.98) |
| Presentation | ||||
| Screening | 2297 | 23 (1.0) | 1.00 (–) | 1.00 (–) |
| Symptoms | 10 294 | 763 (7.4) | 7.91 (5.21 to 12.01) | 3.31 (2.13 to 5.14) |
| Incidental | 592 | 64 (10.8) | 11.98 (7.37 to 19.48) | 3.92 (2.30 to 6.66) |
| Not known | 1854 | 130 (7.0) | 7.46 (4.76 to 11.67) | 2.77 (1.72 to 4.48) |
| Surgery | ||||
| No | 2002 | 489 (24.4) | 1.00 (–) | 1.00 (–) |
| Yes | 13 035 | 491 (3.8) | 0.12 (0.11 to 0.14) | 0.29 (0.24 to 0.35) |
| Radiotherapy | ||||
| No | 3849 | 454 (11.8) | 1.00 (–) | 1.00 (–) |
| Yes | 7335 | 256 (3.5) | 0.27 (0.23 to 0.32) | 0.61 (0.51 to 0.74) |
| Not known | 3853 | 270 (7.0) | 0.56 (0.48 to 0.66) | 0.65 (0.48 to 0.87) |
| Chemotherapy | ||||
| No | 7002 | 520 (7.4) | 1.00 (–) | 1.00 (–) |
| Yes | 4403 | 203 (4.6) | 0.60 (0.51 to 0.71) | 1.49 (1.19 to 1.86) |
| Not known | 3632 | 257 (7.1) | 0.95 (0.81 to 1.11) | 1.20 (0.89 to 1.62) |
| Tamoxifen | ||||
| No | 2493 | 172 (6.9) | 1.00 (–) | 1.00 (–) |
| Yes | 9231 | 601 (6.5) | 0.94 (0.79 to 1.12) | 0.64 (0.51 to 0.80) |
| Not known | 3313 | 207 (6.2) | 0.90 (0.73 to 1.11) | 0.93 (0.70 to 1.24) |
↵* Adjusted for all other factors—that is, based on model that includes all factors.